ClinicalTrials.gov
This table shows the number and types of studies that are registered and for which results are available on ClinicalTrials.gov.
* A study may include more than one type of intervention (that is, a single study may be counted more than once). Because of this, the sum of counts by type of intervention do not equal the total number of interventional studies.
** A total of 539 applicable device clinical trials were submitted as "delayed posting" under the Food and Drug Administration Amendments Act of 2007 (FDAAA). That is, the Responsible Party has indicated that such a trial includes a device not previously approved or cleared by the U.S. FDA for any use. These are not included in the count of trials with at least one device.
*** Results are only required to be submitted for certain studies. For example, results submission is generally not required for observational studies; trials completed before 2008; and trials that include drugs, biologics, or devices not previously approved by the U.S. FDA for any use.
N/A = not applicable
See locations of the recruiting studies here, locations of registered studies here, and numbers of registered studies over time here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.